Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Código da empresaXGN
Nome da EmpresaExagen Inc
Data de listagemSep 19, 2019
CEOMr. John Aballi
Número de funcionários203
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 19
Endereço1261 Liberty Way
CidadeVISTA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92081
Telefone17605601501
Sitehttps://exagen.com/
Código da empresaXGN
Data de listagemSep 19, 2019
CEOMr. John Aballi
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados